S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
Log in

Medpace Stock Price, Forecast & Analysis (NASDAQ:MEDP)

$70.67
-0.20 (-0.28 %)
(As of 11/13/2019 04:00 PM ET)
Today's Range
$70.08
Now: $70.67
$71.23
50-Day Range
$70.15
MA: $77.34
$85.40
52-Week Range
$47.20
Now: $70.67
$86.71
Volume234,600 shs
Average Volume480,514 shs
Market Capitalization$2.55 billion
P/E Ratio27.29
Dividend YieldN/A
Beta1.51
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MEDP
CUSIPN/A
Phone513-579-9911

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$704.59 million
Cash Flow$3.60 per share
Book Value$16.56 per share

Profitability

Net Income$73.18 million

Miscellaneous

Employees2,900
Market Cap$2.55 billion
Next Earnings Date2/24/2020 (Estimated)
OptionableOptionable

Receive MEDP News and Ratings via Email

Sign-up to receive the latest news and ratings for MEDP and its competitors with MarketBeat's FREE daily newsletter.


Medpace (NASDAQ:MEDP) Frequently Asked Questions

What is Medpace's stock symbol?

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

How were Medpace's earnings last quarter?

Medpace Holdings Inc (NASDAQ:MEDP) issued its earnings results on Tuesday, October, 29th. The company reported $0.71 EPS for the quarter, meeting the consensus estimate of $0.71. The company earned $216.20 million during the quarter, compared to analysts' expectations of $217.14 million. Medpace had a net margin of 11.35% and a return on equity of 17.06%. The business's revenue for the quarter was up 20.6% compared to the same quarter last year. During the same period in the previous year, the company earned $0.67 EPS. View Medpace's Earnings History.

When is Medpace's next earnings date?

Medpace is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Medpace.

What guidance has Medpace issued on next quarter's earnings?

Medpace updated its FY19 earnings guidance on Monday, October, 28th. The company provided earnings per share (EPS) guidance of $2.85-2.97 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.91. The company issued revenue guidance of $840-860 million, compared to the consensus revenue estimate of $857.27 million.

What price target have analysts set for MEDP?

4 equities research analysts have issued 12 month price objectives for Medpace's stock. Their forecasts range from $62.00 to $85.00. On average, they expect Medpace's share price to reach $74.67 in the next twelve months. This suggests a possible upside of 5.7% from the stock's current price. View Analyst Price Targets for Medpace.

What is the consensus analysts' recommendation for Medpace?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medpace.

Has Medpace been receiving favorable news coverage?

News stories about MEDP stock have trended positive recently, InfoTrie Sentiment reports. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Medpace earned a coverage optimism score of 2.6 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Medpace.

Who are some of Medpace's key competitors?

What other stocks do shareholders of Medpace own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include EXACT Sciences (EXAS), NVIDIA (NVDA), Alibaba Group (BABA), BioTelemetry (BEAT), Paypal (PYPL), Square (SQ), Intuitive Surgical (ISRG), Okta (OKTA), Arista Networks (ANET) and Paycom Software (PAYC).

Who are Medpace's key executives?

Medpace's management team includes the folowing people:
  • Dr. August James Troendle, Chairman, Pres & CEO (Age 63)
  • Mr. Jesse J. Geiger, CFO & Chief Operating Officer of Laboratory Operations (Age 45)
  • Ms. Susan E. Burwig, Exec. VP of Operations (Age 56)
  • Mr. Stephen P. Ewald, Gen. Counsel & Corp. Sec. (Age 50)
  • Mr. Todd Meyers, VP of Bus. Devel. & Marketing

When did Medpace IPO?

(MEDP) raised $150 million in an IPO on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

Who are Medpace's major shareholders?

Medpace's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (0.86%), Russell Investments Group Ltd. (0.63%), Tributary Capital Management LLC (0.54%), Hillcrest Asset Management LLC (0.46%), Norris Perne & French LLP MI (0.31%) and Scout Investments Inc. (0.27%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Medpace Limited Partnership and Stephen P Ewald. View Institutional Ownership Trends for Medpace.

Which institutional investors are selling Medpace stock?

MEDP stock was sold by a variety of institutional investors in the last quarter, including Virginia Retirement Systems ET AL, Mackay Shields LLC, Convergence Investment Partners LLC, Systematic Financial Management LP, Scout Investments Inc., Tributary Capital Management LLC, Hillcrest Asset Management LLC and Renaissance Group LLC. Company insiders that have sold Medpace company stock in the last year include August J Troendle, Jesse J Geiger, Medpace Investors, Llc and Stephen P Ewald. View Insider Buying and Selling for Medpace.

Which institutional investors are buying Medpace stock?

MEDP stock was bought by a variety of institutional investors in the last quarter, including Congress Asset Management Co. MA, Arabesque Asset Management Ltd, Chicago Equity Partners LLC, State of New Jersey Common Pension Fund D, California Public Employees Retirement System, First Trust Advisors LP, Alberta Investment Management Corp and CIBC Private Wealth Group LLC. View Insider Buying and Selling for Medpace.

How do I buy shares of Medpace?

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Medpace's stock price today?

One share of MEDP stock can currently be purchased for approximately $70.67.

How big of a company is Medpace?

Medpace has a market capitalization of $2.55 billion and generates $704.59 million in revenue each year. The company earns $73.18 million in net income (profit) each year or $2.59 on an earnings per share basis. Medpace employs 2,900 workers across the globe.View Additional Information About Medpace.

What is Medpace's official website?

The official website for Medpace is http://www.medpace.com/.

How can I contact Medpace?

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]


MarketBeat Community Rating for Medpace (NASDAQ MEDP)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  273 (Vote Outperform)
Underperform Votes:  265 (Vote Underperform)
Total Votes:  538
MarketBeat's community ratings are surveys of what our community members think about Medpace and other stocks. Vote "Outperform" if you believe MEDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEDP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel